TriangleAnti-CFH Monoclonal Antibody GT103 (NCT07017829)
Anti-CFH Monoclonal Antibody GT103 trial for Advanced Lung Non-Small Cell Carcinoma (NCT07017829). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced or metastatic STK11-mutated non-small cell lung cancer that progressed on checkpoint treatment and can continue it.
The idea: GT103 targets complement factor H, intended to expose cancer cells to immune destruction. Pembrolizumab blocks PD-1. Both are infused every three weeks for up to two years. Researchers measure survival without progression at six months. Blood samples and tumor tissue are required; archived tissue can replace a new biopsy.
This phase 2 study plans 28 patients. Edwin Yau leads at Roswell Park in Buffalo, one recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.